Regulation of tissue iodothyronine deiodinase activity in a model of prolonged critical illness

Thyroid

Volumn 18, Issue 5, 2008, Pages 551-560

  Debaveye, Yves ^a   Ellger, Björn ^a,b   Mebis, Liese ^a   Darras, Veerle M ^a   Van Den Berghe, Greet ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEIODINASE TYPE I; DEIODINASE TYPE III; IODIDE PEROXIDASE; IODOTHYRONINE; LIOTHYRONINE; PROTIRELIN; SODIUM CHLORIDE; THYROXINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL ILLNESS; ENZYME ACTIVITY; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; IODIDE PEROXIDASE; KIDNEY; LIVER; MALE; MOLECULAR SEQUENCE DATA; RABBITS; THYROTROPIN-RELEASING HORMONE; THYROXINE; TRIIODOTHYRONINE;

EID: 43449135314     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0287     Document Type: Article

References (81)

1. Van den Berghe G 2002 Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 23:370-391.
2. Ellger B, Debaveye Y, Van den Berghe G 2005 Endocrine interventions in the ICU. Eur J Intern Med 16:71-82.
3. DeGroot LJ 1999 Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84:151-164.
4. Wartofsky L, Burman KD 1982 Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome." Endocr Rev 3:164-217.
5. Wiersinga WM 2005 Nonthyroidal illness. In: Braverman LE, Utiger RD (eds) The Thyroid. Lippincot, Philadelphia, pp 246-263.
6. DeGroot LJ 2006 Nonthyroidal illness syndrome. In: DeGroot LJ, Jameson JL (eds) Endocrinology. Elsevier, Philadelphia, pp 2101-2112.
7. Chopra IJ, Chopra U, Smith SR, Reza M, Solomon DH 1975 Reciprocal changes in serum concentrations of 3,3′,5-triiodothyronine (T3) in systemic illnesses. J Clin Endocrinol Metab 41:1043-1049.
8. Fliers E, Alkemade A, Wiersinga WM 2001 The hypothalamic-pituitary- thyroid axis in critical illness. Best Pract Res Clin Endocrinol Metab 15:453-464.
9. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF 1997 Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 82:4032-4036.
10. Alkemade A, Friesema EC, Unmehopa UA, Fabriek BO, Kuiper GG, Leonard JL, Wiersinga WM, Swaab DF, Visser TJ, Fliers E 2005 Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. J Clin Endocrinol Metab 90:4322-4334.
11. Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, van der Vorst E, Lauwers P, Bouillon R, Bowers CY 1998 Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83:309-319.
12. Larsen PR, Silva JE, Kaplan MM 1981 Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr Rev 2:87-102.
13. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89.
14. St Germain DL, Galton VA 1997 The deiodinase family of selenoproteins. Thyroid 7:655-668.
15. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G 2003 Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88:3202-3211.
16. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G 2005 Serum rT3 and T3/rT3 are prognostic markers in critically ill patients and are associated with post-mortem tissue deiodinase activities. J Clin Endocrinol Metab 90:6498-6507.
17. Weekers F, Michalaki M, Coopmans W, van Herck E, Veldhuis JD, Darras VM, Van den Berghe G 2004 Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 145:205-213.
18. Debaveye Y, Ellger B, Mebis L, van Herck E, Coopmans W, Darras V, Van den Berghe G 2005 Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology 146:5604-5611.
19. Darras VM, Berghman LR, Vanderpooten A, Kuhn ER 1992 Growth hormone acutely decreases type III iodothyronine deiodinase in chicken liver. FEBS Lett 310:5-8.
20. Weekers F, van Herck E, Coopmans W, Michalaki M, Bowers CY, Veldhuis JD, Van den Berghe G 2002 A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology 143:764-774.
21. Weekers F, Giulietti AP, Michalaki M, Coopmans W, van Herck E, Mathieu C, Van den Berghe G 2003 Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology 144:5329-5338.
22. Ellger B, Debaveye Y, Vanhorebeek I, Langouche L, Giulietti A, van Etten E, Herijgers P, Mathieu C, Van den Berghe G 2006 Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 55:1096-1105.
23. Pickup JC 2003 Diabetic control and its measurement. In: Pickup JC, Williams G (eds) Textbook of Diabetes. Blackwell, Oxford, UK, p 34.10.
24. Pearce CJ, Byfield PG, Veall N, Himsworth RL 1985 Iodothyronine kinetics in the rabbit: an experimental model. J Endocrinol 106:87-94.
25. National Institutes of Health 1996 Guide for the Care and Use of Laboratory Animals. US NIH Publication no. 86-23, Revised Edition. National Institutes of Health, Bethesda, MD.
26. House of Commons 1986 Guidance on the Operation of the Animals (Scientific Procedures) Act 1986. http://www.archive.official-documents.co.uk/ document/hoc/321/321.htm.
27. Morton D, Abbot D, Barclay R, Close S, Ewbanks R, Gask D, Heath M, Mattic S, Poole T, Seamer J, Southee J, Thompson A, Trussell B, West C, Jennings M 1993 Removal of blood from laboratory mammals and birds. First report of the BVA/FRAME/RSPCA/UFAW Joint Working Group on Refinement. Lab Anim 27:1-22.
28. Fund for the Replacement of Animals in Medical Experiments 2005 FRAME's guidelines on papers involving the use of laboratory animals. www.frame.org.uk/reductioncommittee/bibliointro.htm.
29. Maturlo SJ, Rosenbaum RL, Pan C, Surks MI 1980 Variable thyrotropin response to thyrotropin-releasing hormone after small decreases in plasma free thyroid hormone concentrations in patients with nonthyroidal diseases. J Clin Invest 66:451-456.
30. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY 1997 Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf ) 47:599-612.
31. Darras VM, Kotanen SP, Geris KL, Berghman LR, Kuhn ER 1996 Plasma thyroid hormone levels and iodothyronine deiodinase activity following an acute glucocorticoid challenge in embryonic compared with posthatch chickens. Gen Comp Endocrinol 104:203-212.
32. Schatz DL, Sheppard RH, Steiner G, Chandarlapaty CS, de Veber GA 1969 Influence of heparin on serum free thyroxine. J Clin Endocrinol Metab 29:1015-1022.
33. Mendel CM, Frost PH, Kunitake ST, Cavalieri RR 1987 Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 65:1259-1264.
34. Darras VM, Visser TJ, Berghman LR, Kuhn ER 1992 Ontogeny of type I and type III deiodinase activities in embryonic and posthatch chicks: relationship with changes in plasma triiodothyronine and growth hormone levels. Comp Biochem Physiol Comp Physiol 103:131-136.
35. Matthews JN, Altman DG, Campbell MJ, Royston P 1990 Analysis of serial measurements in medical research. BMJ 300:230-235.
36. Kaptein EM, Feinstein EI, Nicoloff JT, Massry SG 1983 Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. J Clin Endocrinol Metab 57:181-189.
37. Berry MJ, Kates AL, Larsen PR 1990 Thyroid hormone regulates type I deiodinase messenger RNA in rat liver. Mol Endocrinol 4:743-748.
38. Amma LL, Campos-Barros A, Wang Z, Vennstrom B, Forrest D 2001 Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression. Mol Endocrinol 15:467-475.
39. O'Mara BA, Dittrich W, Lauterio TJ, St Germain DL 1993 Pretranslational regulation of type I 5′-deiodinase by thyroid hormones and in fasted and diabetic rats. Endocrinology 133:1715-1723.
40. Boelen A, Platvoet-ter Schiphorst MC, Bakker O, Wiersinga WM 1995 The role of cytokines in the lipopolysaccharide-induced sick euthyroid syndrome in mice. J Endocrinol 146:475-483.
41. Kwakkel J, Wiersinga WM, Boelen A 2006 Differential involvement of nuclear factor-kappaB and activator protein-1 pathways in the interleukin-1beta-mediated decrease of deiodinase type 1 and thyroid hormone receptor beta1 mRNA. J Endocrinol 189:37-44.
42. Boelen A, Kwakkel J, Thijssen-Timmer DC, Alkemade A, Fliers E, Wiersinga WM 2004 Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol 182:315-323.
43. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R 2002 The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf ) 56:655-669.
44. Van den Berghe G, Weekers F, Baxter RC, Wouters P, Iranmanesh A, Bouillon R, Veldhuis JD 2001 Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab 86:3217-3226.
45. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P 1989 Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975-978.
46. Zavacki AM, Ying H, Christoffolete MA, Aerts G, So E, Harney JW, Cheng SY, Larsen PR, Bianco AC 2005 Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. Endocrinology 146:1568-1575.
47. Gong DW, Bi S, Weintraub BD, Reitman M 1998 Rat mitochondrial glycerol-3-phosphate dehydrogenase gene: multiple promoters, high levels in brown adipose tissue, and tissue-specific regulation by thyroid hormone. DNA Cell Biol 17:301-309.
48. LaFave LT, Augustin LB, Mariash CN 2006 S14: insights from knockout mice. Endocrinology 147:4044-4047.
49. Muller S, Seitz HJ 1994 Cloning of a cDNA for the FAD-linked glycerol-3-phosphate dehydrogenase from rat liver and its regulation by thyroid hormones. Proc Natl Acad Sci USA 91:10581-10585.
50. Debaveye Y, Van den Berghe G 2006 Risks and benefits of nutritional support during critical illness. Annu Rev Nutr 26:513-538.
51. Khawaja Y, Dobnig H, Shapiro LE, Surks MI 1990 Increase in hepatic mitochondrial alpha-glycerophosphate dehydrogenase activity after surgical stress in hyperthyroid rats. Endocrinology 127:387-393.
52. Urcelay E, Jareno MA, Menaya J, Parrilla R, Ayuso MS, Martin-Requero A 2000 Cloning and functional characterization of the 5′ regulatory region of the human mitochondrial glycerol-3-phosphate dehydrogenase gene. Lack of 3,5,3′-triiodothyronine responsiveness in adipose tissue. Eur J Biochem 267:7209-7217.
53. Weitzel JM, Kutz S, Radtke C, Grott S, Seitz HJ 2001 Hormonal regulation of multiple promoters of the rat mitochondrial glycerol-3-phosphate dehydrogenase gene: identification of a complex hormone-response element in the ubiquitous promoter B. Eur J Biochem 268:4095-4103.
54. Koenig RJ 2005 Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 15:835-840.
55. Kuiper GG, Kester MH, Peeters RP, Visser TJ 2005 Biochemical mechanisms of thyroid hormone deiodination. Thyroid 15:787-798.
56. Veronikis IE, Braverman LE, Alex S, Fang SL, Norvell B, Emerson CH 1996 Comparison of the effects of propylthiouracil and selenium deficiency on T3 production in the rat. Endocrinology 137:2580-2585.
57. Nguyen TT, Chapa F, DiStefano JJ 3rd 1998 Direct measurement of the contributions of type I and type II 5′-deiodinases to whole body steady state 3,5,3′-triiodothyronine production from thyroxine in the rat. Endocrinology 139:4626-4633.
58. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR 2005 Type 2 iodothyronine deiodinase is themajor source of plasma T3 in euthyroid humans. J Clin Invest 115:2524-2533.
59. Kohrle J, Jakob F, Contempre B, Dumont JE 2005 Selenium, the thyroid, and the endocrine system. Endocr Rev 26:944-984.
60. Kohrle J 2005 Selenium and the control of thyroid hormone metabolism. Thyroid 15:841-853.
61. Schneider MJ, Fiering SN, Thai B, Wu SY, St Germain E, Parlow AF, St Germain DL, Galton VA 2006 Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology 147:580-589.
62. Streckfuss F, Hamann I, Schomburg L, Michaelis M, Sapin R, Klein MO, Kohrle J, Schweizer U 2005 Hepatic deiodinase activity is dispensable for the maintenance of normal circulating thyroid hormone levels in mice. Biochem Biophys Res Commun 337:739-745.
63. Mebis L, Langouche L, Visser TJ, Van den Berghe G 2007 The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab 92:3330-3333.
64. Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, de Herder WW, den Hollander JC, Krenning EP, Visser TJ 1998 Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab 83:2868-2874.
65. Huang SA 2005 Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid 15:875-881.
66. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, Fishman SJ, Larsen PR 2000 Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343:185-189.
67. Huang SA, Fish SA, Dorfman DM, Salvatore D, Kozakewich HP, Mandel SJ, Larsen PR 2002 A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 87:4457-4461.
68. Ruppe MD, Huang SA, Jan de Beur SM 2005 Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase. Thyroid 15:1369-1372.
69. Peeters RP, Debaveye Y, Fliers E, Visser TJ 2006 Changes within the thyroid axis during critical illness. Crit Care Clin 22:41-55.
70. Laurberg P 1984 Mechanisms governing the relative proportions of thyroxine and 3,5,3′-triiodothyronine in thyroid secretion. Metabolism 33:379-392.
71. Laurberg P 1981 Iodothyronine secretion from perfused dog thyroid lobes after prolonged thyrotropin treatment in vivo. Endocrinology 109:1560-1565.
72. Ikeda T, Honda M, Murakami I, Kuno S, Mokuda O, Tokumori Y, Tominaga M, Mashiba H 1985 Effect of TSH on conversion of T4 to T3 in perfused rat kidney. Metabolism 34:1057-1060.
73. Ikeda T, Takeuchi T, Ito Y, Murakami I, Mokuda O, Tominaga M, Mashiba H 1986 Effect of thyrotropin on conversion of T4 to T3 in perfused rat liver. Life Sci 38:1801-1806.
74. Kabadi UM 2006 Role of thyrotropin in metabolism of thyroid hormones in nonthyroidal tissues. Metabolism 55:748-750.
75. Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G 1995 Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 96:2828-2838.
76. Santini F, Hurd RE, Lee B, Chopra IJ 1993 Thyromimetic effects of 3,5,3′-triiodothyronine sulfate in hypothyroid rats. Endocrinology 133:105-110.
77. Escobar-Morreale HF, Obregon MJ, Hernandez A, Escobar del Rey F, Morreale de Escobar G 1997 Regulation of iodothyronine deiodinase activity as studied in thyroidectomized rats infused with thyroxine or triiodothyronine. Endocrinology 138:2559-2568.
78. Friedrichsen S, Christ S, Heuer H, Schafer MK, Mansouri A, Bauer K, Visser TJ 2003 Regulation of iodothyronine deiodinases in the Pax8-/- mouse model of congenital hypothyroidism. Endocrinology 144:777-784.
79. Tabata S, Nishikawa M, Toyoda N, Yonemoto T, Ogawa Y, Inada M 1999 Effect of triiodothyronine administration on reduced expression of type 1 iodothyronine deiodinase messenger ribonucleic acid in streptozotocin-induced diabetic rats. Endocr J 46:367-374.
80. Chanoine JP, Braverman LE, Farwell AP, Safran M, Alex S, Dubord S, Leonard JL 1993 The thyroid gland is a major source of circulating T3 in the rat. J Clin Invest 91:2709-2713.
81. Gereben B, Salvatore D, Harney JW, Tu HM, Larsen PR 2001 The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1). Mol Endocrinol 15:112-124.